Efficacy and Safety of First-Line Ramucirumab Plus Erlotinib for EGFR L858R-Mutated NSCLC in Real-World Practice: A Retrospective Multicenter REAL-SPEED Analysis. - Ishihara M; Kawamura T; Namba Y; Takeyasu Y; Hasegawa Y; Sato Y; Negi Y; Oba T; Sumi T; Hirata H; Funabashi H; Oya Y; et al. (JTO clinical and research reports, 2026)